Repro Med Systems Inc (REPR)

[riskanalyst]

The potential from this stock starts from other patients finding that the SCIG delivery method is better than IVIG method, which looks to be the primary method of delivery for immuno-globulin treatments. This will broaden the application for the Freedom60. Than hopefully the company will find ways to better market their product for delivery of other drugs via SCIG. This seems to be taking place, but has not really taken off. It's been a while since I have looked, but this is probably an area of research about the company I would look into next. This would be an area of significant growth in using their product, before someone else develops the "better mousetrap".